Drug intelligence / Profile preview

NNC0537-1482

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Subcutaneous

Overview

NNC0537-1482 is a C-type natriuretic peptide (CNP) analogue under development by Novo Nordisk for the treatment of heart failure. It is being evaluated in first-in-human Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics when administered subcutaneously in healthy volunteers. The drug represents a new molecular entity and is not yet approved or available for prescription. Its precise mechanism of action has not been fully defined but as a CNP analogue it likely acts on natriuretic peptide pathways relevant to cardiovascular function[1][2][3][6].

Other names: NNC0537-1482NNC-0537-1482NNC 0537-1482NN6537NN-6537NN 6537

Targets

NPR2 (C-type Natriuretic Peptide Receptor B)

Beyond the preview

Go deeper on NNC0537-1482.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0537-1482.

Explore the full profile